News from antisense therapeutics limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 18, 2019, 12:00 ET Antisense Therapeutics Announces Additional preliminary data from the ATL1102 Phase II DMD trial presented at the 2019 Action Duchenne International Conference

Antisense Therapeutics (ASX: ANP/OTC: ATHJY) is pleased to advise that additional preliminary data analyses from the seven patients who have...


Sep 17, 2019, 22:23 ET Positive preliminary results from ATL1102 for DMD Phase II trial

Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that a review of the preliminary data from the 6 patients who have completed...


May 24, 2018, 05:32 ET ATL1103 Phase II trial results published in the European Journal of Endocrinology

Antisense Therapeutics (the "Company" or "ANP") is pleased to announce the acceptance for publication of previously reported positive Phase II...


Sep 22, 2014, 09:00 ET ATL1102 for MS - Phase II trial results published in the leading Medical Journal Neurology

Antisense Therapeutics (the "Company" or "ANP") is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 ...


Sep 02, 2014, 07:19 ET ATL1103 Phase II Trial - Successful Efficacy Results

Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 ...


Jul 29, 2014, 08:00 ET ATL1103 Acromegaly Phase II Trial Dosing Completed

Antisense Therapeutics Limited ("ANP") is pleased to report that dosing of all 26 patients in the Phase II trial of ATL1103 for the potentially...


Apr 01, 2014, 09:45 ET ATL1102 for MS - Toxicology Study Main Findings

Antisense Therapeutics Limited ("ANP" or the "Company") is pleased to advise that results from a chronic toxicity study in monkeys indicate that...


Mar 21, 2014, 10:00 ET ATL1103 Acromegaly Phase II Trial Recruitment Completed

Antisense Therapeutics Limited ("ANP") is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the ...


Mar 17, 2014, 07:20 ET ATL1102 for Stem Cell Mobilisation Trial Commencement

Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept ...


Jan 07, 2014, 05:49 ET Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014

Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that it has been selected to present at the Biotech Showcase 2014...


Dec 23, 2013, 07:15 ET Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial

Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that positive results have been achieved from the interim analysis of a...


Aug 28, 2013, 07:30 ET ANP to present at and attend major US investment, partnering and industry conferences

Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited...